Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study
Authors:
Open Access
- 25 June 2018
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 125 (12) , 1581-1589
Abstract
Objective: To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE).Design and setting: Post hoc analysis of the Hokusai‐VTE study, a multicentre, randomised, double‐blind trial comparing edoxaban with warfarin for acute symptomatic VTE.Population: Women below 50 years receiving edoxaban or warfarin for treatment of VTE.Methods: We collected data on diagnostic measures, treatment, and clinical outcome of abnormal vaginal bleeding events.Main outcome measures: Occurrence of major and clinically relevant nonmajor (CRNM) abnormal vaginal bleeding events.Results: In all, 628 women aged under 50 years were treated with edoxaban and 665 with warfarin. The rate of abnormal vaginal bleeding was 15/100 person‐years (py) (95% CI 11–19) in women receiving edoxaban and 9/100 py (95% CI 6–12) in the warfarin group (hazard ratio: 1.7, 95% CI 1.1–2.5). Major abnormal vaginal bleeding occurred in eight (1.3%) women on edoxaban and in three (0.9%) women receiving warfarin [odds ratio (OR) 2.8; 95% CI 0.8–10.8], and CRNM abnormal vaginal bleeding occurred in 53 (8.4%) women treated with edoxaban and in 37 (5.6%) on warfarin therapy (OR 1.6, 95% CI 1.0–2.4). Over 85% of all vaginal bleeds were characterised by heavy menstrual bleeding. Major bleeds frequently required treatment, and in more than 75% of patients anticoagulant therapy was adjusted. The severity of clinical presentation and course of major and CRNM bleeds was mild in most patients.Conclusions: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin. Reassuringly, most events could be managed conservatively and had a mild outcome.Tweetable Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin.Keywords
Funding Information
- Daiichi-Sankyo
This publication has 30 references indexed in Scilit:
- Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonistsThrombosis Research, 2015
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trialsBlood, 2014
- Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2014
- Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trialsThrombosis and Haemostasis, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategiesThrombosis and Haemostasis, 2013
- Endometrial haemostasis and menstruationReviews in Endocrine and Metabolic Disorders, 2012
- The FIGO Recommendations on Terminologies and Definitions for Normal and Abnormal Uterine BleedingSeminars in Reproductive Medicine, 2011
- The Risk of Deep Venous Thrombosis Associated With Injectable Depot–Medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine DeviceArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case–control study using the General Practice Research DatabaseBJOG: An International Journal of Obstetrics & Gynaecology, 2008